IRONWOOD PHARMACEUTICALS INC

Ironwood Pharmaceuticals reported strong second quarter 2026 results, with total revenue reaching $113 million and GAAP net income of $51 million. Building on this performance, the company raised its full-year 2026 financial guidance for LINZESS U.S. net sales, total revenue, and adjusted EBITDA. Additionally, Ironwood repaid $200 million in convertible notes and initiated the confirmatory Phase 3 STARS-2 trial for apraglutide, its lead pipeline asset.

Ironwood Pharmaceuticals held its 2026 Annual Meeting of Stockholders, where key proposals were approved. Stockholders voted to approve an amendment to the company's Amended and Restated 2019 Equity Incentive Plan, increasing the shares available for issuance by 10,000,000. Additionally, eight director nominees were elected, executive compensation was approved on a non-binding advisory basis, and KPMG LLP was ratified as the independent registered public accounting firm for 2026.

Ironwood Pharmaceuticals, Inc. announced the full repayment of $200.0 million in aggregate principal amount of its 1.50% convertible senior notes due 2026. The repayment was made on schedule using the company's available cash on hand. No conversions were exercised by noteholders, and the associated capped call transactions terminated upon expiry.

Ironwood Pharmaceuticals Inc. announced the appointment of Mr. Silver as the company's interim chief financial officer and principal financial officer, effective May 19, 2026. In connection with this new role, the Committee approved a monthly interim assignment fee of $12,250 for Mr. Silver. Additionally, Mr. Silver received a grant of 25,000 restricted stock units, which will vest over two years.

Gregory Martini resigned from his position as Senior Vice President, Chief Financial Officer of Ironwood Pharmaceuticals, effective May 15, 2026. His resignation is not due to any disagreement with the company's financial reporting. Ronald Silver, currently the Senior Vice President, Corporate Controller and Chief Accounting Officer, will assume the role of interim chief financial officer and principal financial officer, effective the same date. Silver has been with the company since June 2018, holding various accounting and financial reporting roles.

Ironwood Pharmaceuticals reported a significant financial turnaround for Q1 2026, with collaborative arrangements revenue increasing by 159% to $106.5 million, up from $41.1 million in Q1 2025. The company swung from a net loss of $37.4 million in the prior year to a net income of $40.8 million, resulting in basic EPS of $0.25. This performance was primarily driven by strong LINZESS sales in the U.S. and reduced operating expenses.

Ironwood Pharmaceuticals reported strong first quarter 2026 financial results, driven by a 97% year-over-year increase in LINZESS U.S. net sales to $273 million. The company achieved total revenue of $107 million, GAAP net income of $41 million, and adjusted EBITDA of $77 million, while maintaining its full-year 2026 financial guidance. Additionally, Ironwood is progressing with its apraglutide Phase 3 confirmatory trial and received priority review for a LINZESS sNDA for functional constipation in young children.

Ironwood Pharmaceuticals will hold its 2026 Annual Meeting of Stockholders virtually on June 16, 2026. Stockholders will vote on the election of eight director nominees, an advisory resolution on named executive officer compensation, and the ratification of KPMG LLP as the company's auditors for 2026. A key proposal includes approving an amendment to the 2019 Equity Incentive Plan to increase available shares by 10,000,000. The board recommends voting "for" all proposals.